Tirofiban, marketed under the brand name Aggrastat, is a potent medication that belongs to the class of glycoprotein IIb/IIIa receptor inhibitors.

The disclosed CS5001 is an ADC targeting ROR1, featuring a unique design.

Adjuvants are substances that are added to vaccines to enhance the body's immune response to an antigen (a substance that can trigger an immune response).

Biotheryx, Inc. revealed that their Investigational New Drug application for BTX-9341, an innovative bifunctional degrader targeting cyclin-dependent kinase 4/6 (CDK4/6).

Axicabtagene ciloleucel, branded as Yescarta, is a revolutionary immunotherapy medication developed by Kite Pharma, a subsidiary of Gilead Sciences.

CMG901 (AZD0901) is a potentially first-in-class antibody-drug conjugate targeting Claudin 18.2, conjugated with monomethyl auristatin E (MMAE) as the payload.

A dose escalation trial, also known as a dose-ranging study, is a type of clinical trial design used primarily in Phase I of drug development.

Neurogene revealed promising safety results from its Phase 1/2 study on NGN-401, a gene therapy for Rett Syndrome.

Mometasone topical, commercially known as Elocon, is a potent corticosteroid medication developed by Novartis Pharmaceuticals Corporation.

May 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Seamless Phase I/II clinical trials are a type of clinical trial design that combines elements of both Phase I and Phase II trials into a single study.

Merus Reveals FDA Approval and Expedited Assessment of BLA for Zeno to Manage NRG1+ Lung and Pancreatic Cancer.